title: Mayo Clinic experience with allogeneic and syngeneic bone marrow transplantation, 1982 through 1990.
abstract: Between April 1982 and July 1990, 101 patients underwent allogeneic or syngeneic bone marrow transplantation at the Mayo Clinic. This patient population consisted of 30 with acute nonlymphocytic leukemia, 25 with acute lymphoblastic leukemia, 29 with chronic granulocytic leukemia, and 17 with other diseases (aplastic anemia in 7, myelodysplastic syndrome in 5, and lymphoma in 5). The results achieved in our patients who underwent transplantation in first complete remission of both acute nonlymphocytic leukemia and acute lymphoblastic leukemia compare favorably with previously reported results. Only 1 of 15 patients (7%) with acute nonlymphocytic leukemia and 2 of 8 patients (25%) with acute lymphoblastic leukemia who underwent transplantation in first complete remission had a relapse. Thus, we recommend early bone marrow transplantation during initial complete remission for patients with either of these disorders who have adverse prognostic factors. In contrast, of 12 patients with either acute nonlymphocytic leukemia or acute lymphoblastic leukemia who underwent transplantation during relapse, 11 died within 6 months. Therefore, such patients should be offered new experimental treatments. Our patients with chronic granulocytic leukemia fared better when they underwent transplantation early during the course of their disease rather than during the accelerated or blast phase. Prospective studies are needed to determine the best approach in these patients.
authors.affiliation: Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905.
authors.forename: L
authors.initials: L
authors.lastname: Letendre
authors.forename: H C
authors.initials: HC
authors.lastname: Hoagland
authors.forename: S B
authors.initials: SB
authors.lastname: Moore
authors.forename: M G
authors.initials: MG
authors.lastname: Chen
authors.forename: D A
authors.initials: DA
authors.lastname: Gastineau
authors.forename: M A
authors.initials: MA
authors.lastname: Gertz
authors.forename: T M
authors.initials: TM
authors.lastname: Habermann
authors.forename: M R
authors.initials: MR
authors.lastname: Litzow
authors.forename: P
authors.initials: P
authors.lastname: Noël
authors.forename: L A
authors.initials: LA
authors.lastname: Solberg
mesh_terms: D000046:Academic Medical Centers; D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000592:standards* / Q000639:trends; D002648:Child; D002675:Child, Preschool; D002985:Clinical Protocols / Q000592:standards; D003586:Cytomegalovirus Infections / Q000453:epidemiology / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D015994:Incidence; D007938:Leukemia / Q000628:therapy*; D008297:Male; D008910:Minnesota / Q000453:epidemiology; D011379:Prognosis; D012008:Recurrence; D012074:Remission Induction / Q000379:methods; D015996:Survival Rate; D014184:Transplantation, Homologous / Q000009:adverse effects / Q000592:standards* / Q000639:trends; D014185:Transplantation, Isogeneic / Q000009:adverse effects / Q000592:standards* / Q000639:trends